The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.

doi:10.3324/haematol.2014.108183

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.

Haematologica - 1 Apr 2015

Rossi Davide, Bruscaggin Alessio, La Cava Piera, Galimberti Sara, Ciabatti Elena, Luminari Stefano, Rigacci Luigi, Tucci Alessandra, Pulsoni Alessandro, Bertoldero Giovanni, Vallisa Daniele, Rusconi Chiara, Spina Michele, Arcaini Luca, Angrilli Francesco, Stelitano Caterina, Merli Francesco, Gaidano Gianluca, Federico Massimo, Palumbo Giuseppe A

Abstract excerpt

Though most follicular lymphoma biomarkers rely on tumor features, the host genetic background may also be relevant for outcome. Here we aimed at verifying the contribution of candidate polymorphisms of FCγ receptor, DNA repair and detoxification genes to prognostic stratification of follicular lymphoma treated with immunochemotherapy. The study was based on 428 patients enrolled in the FOLL05 prospective trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Kaplan-Meier Estimate

Share to Lymphoma, Follicular

Share to MutL Protein Homolog 1

Share to Neoplasm Grading

Share to Receptors, IgG

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 25596266
DOI: 10.3324/haematol.2014.108183
PMCID: PMC4380725

Genes

MLH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.PMID 25596266Read ↗

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.Semantic proximity Read ↗

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.Semantic proximity Read ↗

The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.Semantic proximity Read ↗

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016Semantic proximity Read ↗

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.Semantic proximity Read ↗

The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.Semantic proximity Read ↗

Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.Semantic proximity Read ↗

Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.Semantic proximity Read ↗

A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival.Semantic proximity Read ↗

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.Semantic proximity Read ↗

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.